Study: 38% of FDA Advisory Meetings Included a Patient or Consumer Rep Tied to a Pharma-Funded Group
FDA Advisory Panels & Pharma-Funded Patient Reps
The seats meant for patients at FDA drug reviews were often filled by people from groups the drug industry helps pay for, and most of the time, nobody said so.
The seats reserved for patients and consumers on the Food and Drug Administration's advisory committees exist for one reason: to make sure the public, not just scientists and companies, has a voice when the agency weighs whether a drug is safe and effective. A new peer-reviewed analysis suggests that voice has frequently come from people connected to organizations bankrolled by the pharmaceutical industry.
The study, published October 7, 2026, in Health Affairs Scholar, found that between 2013 and 2022, nearly two in five FDA advisory committee meetings (38%) included a patient or consumer representative who was actively involved with an advocacy organization that received pharmaceutical funding. [1]
More pointedly, 11% of meetings — more than one in ten — included a representative affiliated with an organization funded by the sponsor of the very drug under review. [1]
What the researchers measured
The analysis was conducted by Genevieve P. Kanter, PhD, of the University of Southern California's Sol Price School of Public Policy and the Leonard D. Schaeffer Institute for Health Policy and Economics, and Toni Mankowitz of the Schaeffer Institute. [1]
The researchers examined the advocacy organizations in which patient and consumer representatives were actively involved during the year they attended an FDA advisory committee meeting, and then determined whether those organizations received industry money. [1]
The pattern was not evenly distributed. On several FDA committees, more than half of meetings included a representative with such ties. [1] The authors concluded that the findings point beyond isolated cases to a systemic problem that warrants policy attention from the FDA. [1]
Most ties were not disclosed
According to reporting by STAT, most of these organizational relationships were not disclosed at the meetings themselves. [2] That matters because advisory meetings are public proceedings: other panelists, journalists, and patients watching cannot account for a financial relationship they do not know exists.
A gap in the conflict-of-interest rules
FDA advisory committees are made up primarily of scientific experts, but each also includes a patient representative and a consumer representative. [1] The agency has built out conflict-of-interest policies for its scientific members over the years. Its rules for patient and consumer representatives are far less developed — particularly when it comes to industry funding of the advocacy groups those representatives belong to. [1][2]
In practice, this means a representative's personal finances may be screened while the funding sources of the organization they lead or work with go unexamined.
Why advisory votes carry weight
Advisory committee recommendations are not binding, but the FDA usually follows them. A separate analysis of 409 human drug advisory committee meetings held from 2010 to 2021 found that 88% of FDA regulatory actions aligned with the committees' votes — including on new approvals, supplemental approvals, and safety actions. [3]
What the study does not show
The findings document funding relationships, not influence. The published abstract does not report whether representatives with these ties voted differently from other committee members, and an organization's acceptance of industry money does not by itself establish that any individual representative was swayed. [1][4]
Patient representatives also bring something the rest of the panel cannot: firsthand experience living with a disease or caring for someone who has one. Kanter herself has described that perspective as valuable, while noting that patient representatives do not undergo the same scientific-expertise screening as other members. [5]
Part of a broader pattern
Industry funding of patient advocacy groups has drawn scrutiny before. A 2025 investigation by the Project On Government Oversight found that most of the patient and consumer groups the FDA included in a round of stakeholder meetings tied to prescription drug user fee negotiations had received pharmaceutical industry funding. [6]
In 2025, then-FDA Commissioner Marty Makary moved to limit industry employees serving on advisory committees and said the agency would increase input from patients and caregivers. [5] The new study raises a follow-up question that policy has not yet answered: who funds the organizations those patients come from?
Timing: the FDA is filling these seats now
The study arrives as the agency is actively recruiting. On September 30, 2026, the FDA announced a nationwide drive to fill advisory committee vacancies, publishing two Federal Register notices — one for scientific voting members and one for consumer representatives. [7][8] Consumer representative nominations are due by November 15, 2026. [7]
Acting FDA Commissioner Kyle Diamantas said the panels provide "independent expertise and rigorous scrutiny." [9]
According to a review of the notice by Medical Daily, the FDA asks candidates about their own financial holdings, employment, and research grants, and asks them to list the consumer or community organizations they participate in — but does not ask about the funding those organizations receive. [4] That is precisely the gap the USC study identifies.
What readers can do
Check the roster. Before or after an advisory meeting, review the FDA's advisory committee pages for member rosters and briefing materials. [10]
Follow the money. Many advocacy organizations list corporate donors in annual reports or on their websites. Look up the organizations patient and consumer representatives are affiliated with.
Watch the opening. Note whether conflicts of interest are discussed at the start of the meeting, and whether organizational funding is mentioned at all.
The bottom line
The patient's voice at the FDA is meant to be a counterweight. When more than a third of meetings include a representative tied to a pharma-funded group — and those ties often go unmentioned — the public is left unable to judge whose interests that voice reflects.
Vital Biomedical News is reader-supported and accepts no funding from pharmaceutical or medical device companies.
References
Kanter GP, Mankowitz T. Prevalence of ties to industry-funded organizations among patient and consumer representatives on FDA advisory committees. Health Affairs Scholar. Published October 7, 2026. doi:10.1093/haschl/qxag269. https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag269/8876111
Silverman E. Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds. STAT. October 13, 2026. https://www.statnews.com/pharmalot/2026/10/13/many-patient-and-consumer-reps-on-fda-advisory-committees-ties-to-groups-funded-by-pharma/
Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010–2021. PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329213/
James J. More Than 1 in 10 FDA Advisory Meetings Had a Representative From a Group the Drugmaker Funded. Medical Daily. October 14, 2026. https://www.medicaldaily.com/fda-advisory-committee-patient-consumer-reps-industry-funding-study-479963
Banning Industry From FDA Adcomms Won't 'Move the Needle Much' in Makary, RFK's Fight Against COIs. BioSpace. 2025. https://www.biospace.com/fda/banning-industry-from-fda-adcomms-wont-move-the-needle-much-in-makary-rfks-fight-against-cois
Drug Money: In FDA Meetings, "Voice" of the Patient Often Funded by Drug Companies. Project On Government Oversight. 2025. https://www.pogo.org/investigates/in-fda-meetings-voice-of-patient-often-funded-by-drug-companies
FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees. The ASCO Post. October 2026. https://ascopost.com/news/october-2026/fda-launches-effort-to-expand-scientific-expertise-consumer-voice-to-advisory-committees/
Food and Drug Administration. Request for Nominations for Individuals and Consumer Organizations for Advisory Committees. Federal Register. October 1, 2026. https://public-inspection.federalregister.gov/2026-20065.pdf
FDA Expands Recruitment for Advisory Committee Vacancies. MyChesCo. October 2026. https://www.mychesco.com/a/news/national/fda-expands-recruitment-for-advisory-committee-vacancies/
U.S. Food and Drug Administration. Advisory Committees. https://www.fda.gov/advisory-committees